Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have been successful.
What is next for Dogecoin? President XI going to endorse it?
Are we breaking the down trend?
I tend to agree. This move is a prelude to a positive development, imo. They would not get someone Dr. Sohn right BEFORE a huge negative. I am sure she signed a NDA and knows what is coming up and why certain things (RS) need to happen.
And insiders hold more than 50 percent of OS. Why spend for a bogus meeting when a meeting of four can say yay or nay?
Full disclosure. I picked up more at .08. If panic selling continues, I just say THANKS in advance
PS...this is not a logistics company with no intellectual property.
No need to pump. Panic is not a strategy. But, hold, accumulate or sell. Everyone has a choice.
There is a real reason for them to do this filing. You have to inform the investing public of an intent to do a RS. Mgmt to date has not shown they are using equity to do anything other to expand their pipeline and prepare for clinical trials.
I have seen a Notice to Shareholders before and it turned out that the company actually had a partner that wanted to partner up, but only if the company was listed. Depending when it happens, it could be a modest split.
Much rather have a stock on Nasdaq o r NYSE Small Cap with a real partner than hoping for a Stocktwit to come out
Pretty sloppy accounting. Shareholder lawsuits may be next.
Monday trading should be interesting if it starts strong and gives potential sellers a reason to hold. If CUBT could close above .13 on another day of HIGH volume, momentum traders will come in.
Bet you are right, 3F. I saw some talk on Stocktwits, Twitter and Seeking Alpha. If just may be rumor, hope--whatever.
But CUBT is getting on other people's radar screens.
CUBT is waking up
Getting into crypto miners focusing on Bitcoin, imo, is the best way to go. And companies that have the latest in crypto mining machines have the best cost structure. Taking into account power costs
Great volume. Heavy buying this morning took out weaker hands, impatient hands. Hands that complain and may move on finally.
There should be some update on the Form 10 filing too. Maybe it is finally going to be filed.
The latest on AMD
Q&A with Rajendra Apte, M.D., Ph.D.
August 5, 2021
Age-Related Macular Degeneration Clinical Research NEI
Rajendra Apte, M.D., Ph.D., studies the cellular and molecular basis of age-related macular degeneration. Apte is the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences and Vice Chair of Innovation and Translation at the Washington University School of Medicine in St. Louis. His clinical perspective “Age-Related Macular Degeneration,” appeared today in the New England Journal of Medicine.
Rajendra Apte
What’s the difference between dry and wet AMD? Can I have both?
Dry and wet AMD both affect the light-sensing tissue in the back of the eye called the retina. Dry AMD is characterized by deposits underneath the retina called drusen. Wet AMD is characterized by abnormal, leaky blood vessels in the retina. Most AMD starts as the dry form but can progress to wet or advanced dry AMD in one or both eyes. Dry AMD-related vision loss is due to the death of retinal cells and is not reversible. Wet AMD-related vision loss is due to fluid build-up in the retina and can sometimes be reversed with treatment.
Will I go completely blind?
When diagnosed with AMD, patients are often afraid that they will lose all their vision. Even advanced AMD seldom leads to total blindness. But it can destroy the central vision that enables us to read, drive, and recognize faces. Monitoring and treatment aims to prevent or slow worsening.
What can I do to help my AMD?
Regular, comprehensive eye exams are especially important. I advise AMD patients to monitor their vision with tools such as an Amsler grid to help identify AMD-related changes early and seek care promptly if any are detected. Smoking and high blood pressure are known risk factors for AMD. Smokers should quit and patients with hypertension should work with their health care provider to get it under control. AREDS2 nutritional supplements can reduce AMD worsening, as shown in the NEI-funded Age-Related Eye Disease Studies (AREDS 1 and AREDS2).
Amsler Grid
The Amsler Grid. The Amsler Grid provides an easy way to test whether or not your central vision has changed. It can recognize even small changes in your vision.
If you need reading glasses, wear them when you look at the Amsler grid. The grid should be at the same distance from your eyes as your usual reading material – about 14 inches. Test both eyes, one at a time, to see if any parts of the grid look distorted, missing, or dark. Mark the areas of the chart that you’re not seeing properly and bring it with you to your next eye exam.
Will I need eye injections forever for my wet AMD?
As I recently stated in The New England Journal of Medicine, drugs that target vascular endothelial growth factor (VEGF) —Lucentis, Avastin, Eylea, and Beovu — have revolutionized treatment for wet AMD, which causes the majority of AMD-related vision loss. Unfortunately, the only way to give these drugs is by injection into the eye. On average, patients receive 7-8 injections during the first 12 months; however, the frequency and duration of injections is determined by disease activity and treatment response. Patients should not stop injections without consulting with their eye care provider.
Would cataract surgery help me?
People with AMD often also have cataracts. Many patients are afraid to get cataract surgery for fear of worsening their AMD or that surgery won’t help them because they have AMD. Patients should discuss the risks and benefits of cataract surgery. The appropriate timing of cataract surgery is especially important for patients with wet AMD.
What can we expect in the future?
Researchers are exploring a variety of new approaches to AMD treatment, including pharmacologic, stem cell-, and gene therapy-based strategies. The development of new AMD therapies like anti-VEGF drugs wouldn’t have been possible without patient participation in clinical trials; however, I encourage patients to talk with their doctor to better understand the potential risks and benefits prior to enrolling in a clinical trial.
Are there any visual aids that can help me?
I encourage patients with AMD-related vision loss to seek help from a vision rehabilitation specialist. Such specialists can guide patients on how to make the best of their vision through visual aids for magnification and improved lighting. They can also offer tips and strategies to best manage vision loss.
Reference
Apte, Rajendra S. New England Journal of Medicine 2021;385:539-47. DOI: 10.1056/NEJMcp2102061This link is external to nei.nih.gov and will open in a new browser window or tab..
Learn more about AMD
Learn more about NEI-funded AMD research
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/This link is external to nei.nih.gov and will open in a new browser window or tab..
Last CEO blog was in Early August.
“In theory there is no difference between theory and practice. In practice there is.” ~Yogi Berra
While it’s sometimes hard to follow the logic of the inestimable Mr. Berra, in this case, it isn’t. In the life sciences, and particularly in the clinical development of therapeutics, the success of your plans is a product of the quality of the people you charge to execute your theories, in practice. Those of you who follow Curative know that we have made a concerted effort to recruit the inventors of the technologies we have licensed to help steer the “practice”. So, it should not be a surprise that we are talking to the National Eye Institute (NEI) at NIH about collaborating on the first clinical trials of our reformulation of metformin into an eye drop to treat age-related macular degeneration.
The first trial is being designed to treat patients with both intermediate dry AMD, and geographical atrophy, which you can think of as late-stage dry AMD. Macular degeneration is a leading cause of irreversible blindness and visual impairment in the world. As many as 15 million people in the U.S. alone and as many as 200 million people worldwide have some form of age-related macular degeneration and those numbers are expected to double over the next two decades as populations age. The risk of getting advanced age-related macular degeneration increases from 2% for those individuals in their 50’s to nearly 30% for those over the age of 75. The “dry” form of age-related macular degeneration accounts for approximately 90% of all the cases.
Age-related macular degeneration is a (currently) irreversible destruction of the macula, which leads to the loss of the sharp, fine detail vision required for activities like reading, driving, recognizing faces, and even seeing the world in color. At Curative, we believe that our patent-pending eye drop may slow down or even stop this degenerative process. It is possible for researchers to test and see the effects of our drug on the various mechanisms involved in this downward spiral, and the results are encouraging. However, there is no actual “animal” model that recreates the disease. The potential efficacy of this drug will only be revealed in well controlled clinical trials of actual patients.
And so that brings us back to the National Eye Institute. We have stated publicly that our goal is to have an IND filed with the FDA near the end of this year and be in clinical trials in Q1 of 2022. NEI is considered the gold standard in the world of ophthalmologic research. Indeed, most of the world’s other prestigious research institutes are “ranked” by how much support they receive from NEI. Our discussions with NEI are just that at this point, discussions. However encouraging those discussions are, no one should take this as a statement of anything else at this time. As Yogi also famously said, “It ain’t over ‘til it’s over.”
Seems that a word from the CEO would be welcome again.
No mention of HIVE in this article on crypto today.
China's Crackdown on Cryptocurrencies and its Impact on Crypto Mining Companies Outside the Country
https://www.benzinga.com/markets/cryptocurrency/21/10/23414798/chinas-crackdown-on-cryptocurrencies-and-its-impact-on-crypto-mining-companies-outside-the
You may be right that Ethereum is a drag on HIVE. Bitcoin is the focus for most serious investors.
Seems like those companies JUST getting into the mining biz will be buying the latest and greatest and most efficient machines for BITCOIN mining. Ethereum seems to be an "also ran".
Saw this presentation on one just starting up.
https://journey.ct.events/view/ba46df27-8e72-43e4-8591-246e25ae465f
Clarification of "False News" here
No insider (including Advisory Board or Special Advisor members) can sell any shares received in compensation. Share have to be registered--with a Registration Statement. They would have to be filed with the SEC.
There are no registration statements filed for these individuals--so they cannot be sold.
There is a reason for share compensation not being immediately liquid--to protect investors and align the interests of those receiving shares in lieu of cash with those shareholder investing in the open market.
Without these restrictions, there would be the temptation to agree to do work over months and/or years (or be available for consulting, meetings etc). and just selling as soon as they receive the shares. Without the registration statement, they do not have any registered shares to sell.
Whether you pay the company for a roofing job before you see the work complete or use shares--you never pay in advance of the work.
SUMMARY? There are no shares held by insiders that can be sold in the near term (within the next 12 months)
It does seem odd that they have not become bottom line profitable--and they keep on selling shares.
The biggest risk to a second tier China-centric stock like KNDI is that the investment risk has increased. If Taiwan problems hit the headlines, more investors will be getting OUT of stocks like this one.
Thanks to President XI
3F--agreed on the hug potential of the vaccine possibilities with the IMT504 drug. There is a great deal of motivation and incentive for the FDA, NIH and the Feds to fast track promising drugs that could enhance the effectiveness of vaccines.
Adding IMT504 to a vaccine shot that could extend its effectiveness beyond the current 6-8 months would be huge.
Much more work to prove that--but they obviously have a reason to stake out a high risk patient group to minimize objections for the trial.
Dr. Sohn Video
There is accumulation going on. From weak hands to stronger hands
Just people who own stock
Seems like fraud or theft if what you say is true.
Please direct me to the evidence. Should be somewhere
Numbers are not ignored forever .
He may be pulling your chain.
As for me, that last news hooked me for another 75k shares. Expecting news on the filing of the IND. But that vaccine potential could be bigger than just kidney failure patients
gltu
Nice payout. Hope no one was short and has to come up with the divvy.
We should all post some charts of CUBT on some other boards to get more eyes on it. We may be close to a breakout with more volume. Why not give it a little helps with new investors?
I will do my part.
REMINDER:
https://www.healthline.com/health-news/can-metformin-help-with-macular-degeneration#:~:text=A%20new%20study%20found%20that%20people%20with%20type,stress%20is%20a%20likely%20reason%20for%20this%20benefit.
And the Investigational New Drug (IND) application will be filed before the end of the year.
Would like to see a large partner be included with that filing.
BTCM needs to report quarter to quarter revenue growth that validates their business plan is working.
It is one thing to buy crypto mining machines--and another to operate in a low cost-high margin environment.
There seems to be a real disconnect with some that expect a small biotech to come out with news all the time--or anything such as what they are trying to do, who they are talking to, what negotiations they are in, etc. --just to reassure shareholders that they are doing something.
I would be more alarmed if they did any of the above because being that transparent would not be for the long term benefit of the company and its shareholders.
And you would chase away potential advisory board members (and their employers) if the company came off as pumpy.
Which brings up another point--there is way more risk to an advisory board member for associating with a scam company than any compensation in shares could offset.
The fact that accomplished medical professionals with impressive resumes' are coming on board is a form of due diligence for ME.
Previous PR with MABT
https://www.globenewswire.com/en/news-release/2020/10/09/2106348/0/en/Connectyx-Technologies-Holdings-Group-Inc-Announces-Definitive-Agreement-with-Mid-Atlantic-BioTherapeutics-Inc-for-Treatment-of-Symptomatic-Rabies.html
These agreements make CUBT more attractive to potential partners and/or substantial investors. With the IND filing coming in the Fourth Quarter for Metformin (note spelling,iRobot) and clinical trials starting in First Quarter 2022, CUBT is building enterprise value.
N95 will be the "go to" mask in the future.
This recent news looks like they are expanding their license to include a way to attach CUBT to MABT's promising drug not just for rabies, which is understandably as smaller market than a Covid vaccine "enhancer or extender". Initially focusing on Kidney Failure patients (like an "orphan drug" situation), if it looks promising for that small population with higher antibody titers, there may be interest from potential partners.
IMT504 has been granted orphan drug designation in the US, which provides significant benefits including tax credits, market exclusivity and waiver of certain FDA fees. Rabies is one of only 14 diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria.
Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged, and their value has increased. In 2016–2018, the value of a voucher ranged from $125 million to $200 million.
Agreed that the smart move is to focus on Bitcoin.
Energy efficient, green miners will attract ESG investors
Chinese companies are going to have a hard time. No one trusts their accounting nor the CCP.
And when they attack Taiwan, the shorts will win big time.
The search for a really effective Covid vaccine is still on. Lots of opportunity for rapid testing, antibody tests and vaccines that last longer.